Commonwealth Equity Services’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-49,333
| Closed | -$150K | – | 4318 |
|
|
2024
Q4 | $150K | Sell |
49,333
-28,708
| -37% | -$125K | ﹤0.01% | 3830 |
|
|
2024
Q3 | $405K | Sell |
78,041
-31,876
| -29% | -$158K | ﹤0.01% | 3082 |
|
|
2024
Q2 | $282K | Buy |
109,917
+1,541
| +1% | +$5.26K | ﹤0.01% | 3349 |
|
|
2024
Q1 | $533K | Sell |
108,376
-2,768
| -2% | -$16.4K | ﹤0.01% | 2766 |
|
|
2023
Q4 | $977K | Buy |
111,144
+12,015
| +12% | +$98.4K | ﹤0.01% | 2195 |
|
|
2023
Q3 | $1.14M | Buy |
99,129
+3,478
| +4% | +$66.9K | ﹤0.01% | 1990 |
|
|
2023
Q2 | $2.42M | Buy |
95,651
+6,883
| +8% | +$214K | ﹤0.01% | 1497 |
|
|
2023
Q1 | $2.86K | Sell |
88,768
-51
| -0.1% | -$1.59K | 0.01% | 1322 |
|
|
2022
Q4 | $1.64M | Buy |
88,819
+12,994
| +17% | +$297K | ﹤0.01% | 1633 |
|
|
2022
Q3 | $2.05M | Buy |
75,825
+43,012
| +131% | +$873K | 0.01% | 1404 |
|
|
2022
Q2 | $453K | Buy |
32,813
+2,500
| +8% | +$38.5K | ﹤0.01% | 2479 |
|
|
2022
Q1 | $591K | Buy |
30,313
+5,598
| +23% | +$84.9K | ﹤0.01% | 2390 |
|
|
2021
Q4 | $403K | Buy |
24,715
+3,555
| +17% | +$59.3K | ﹤0.01% | 2708 |
|
|
2021
Q3 | $589K | Buy |
21,160
+6,023
| +40% | +$172K | ﹤0.01% | 2349 |
|
|
2021
Q2 | $448K | Sell |
15,137
-148
| -1% | -$4.27K | ﹤0.01% | 2556 |
|
|
2021
Q1 | $427K | Buy |
15,285
+2,103
| +16% | +$58.2K | ﹤0.01% | 2458 |
|
|
2020
Q4 | $373K | Buy |
13,182
+588
| +5% | +$15.2K | ﹤0.01% | 2381 |
|
|
2020
Q3 | $316K | Buy |
+12,594
| New | +$330K | ﹤0.01% | 2315 |
|
Other funds holding RVNC
Commonwealth Equity Services's RVNC Position: Q1 2025 in Review
Commonwealth Equity Services sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 49,333 shares — an estimated $150K sold.
Commonwealth Equity Services first reported a position in RVNC in Q3 2020 and held it in 18 quarters. The position peaked at $2.42M in Q2 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Commonwealth Equity Services reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Commonwealth Equity Services sold 49,333 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $150K.
- Commonwealth Equity Services first reported a position in Revance Therapeutics, Inc. in Q3 2020 and held it in 18 quarters.
- Commonwealth Equity Services's Revance Therapeutics, Inc. position peaked at $2.42M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Commonwealth Equity Services's 13F filing for Q1 2025, filed 9 May 2025.